Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study

New insights after the first 1000 liver transplantations at The University of Hong Kong

(2016) See Ching Chan et al.   Asian Journal of Surgery

Safety of mTOR inhibitors in adult solid organ transplantation

(2016) Pedro Ventura-Aguiar et al.   Expert Opinion On Drug Safety

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma

(2016) Edward K. Geissler et al.   TRANSPLANTATION

Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital

(2016) Junichi Togashi et al.   HEPATOBILIARY SURGERY AND NUTRITION

OPTN/SRTR 2013 Annual Data Report: Liver

(2015) W. R. Kim et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience

(2015) Italo Bonadio et al.   CLINICAL TRANSPLANTATION

mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?

(2015) Christophe Duvoux et al.   Transplantation Reviews

Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation

(2014) M. Sterneck et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Liver transplantation

(2014) Manuel Rodríguez-Perálvarez et al.   Current Opinion in Organ Transplantation

Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review

(2014) Evangelos Cholongitas et al.   TRANSPLANT INTERNATIONAL

Section 5. Further Expanding the Criteria for HCC in Living Donor Liver Transplantation

(2014) Kwang-Woong Lee et al.   TRANSPLANTATION

Long-Term Outcome of Living Donor Liver Transplantation for Patients With Alcoholic Liver Disease

(2014) C.-S. Ahn et al.   TRANSPLANTATION PROCEEDINGS

Strategies for the management of adverse events associated with mTOR inhibitors

(2014) Bruce Kaplan et al.   Transplantation Reviews

Why does living donor liver transplantation flourish in Asia?

(2013) Chao-Long Chen et al.   Nature Reviews Gastroenterology & Hepatology

Living-Donor Liver Transplantation Associated With Higher Incidence of Hepatocellular Carcinoma Recurrence Than Deceased-Donor Liver Transplantation

(2013) Min-Su Park et al.   TRANSPLANTATION

Everolimus With Reduced Tacrolimus Improves Renal Function inDe NovoLiver Transplant Recipients: A Randomized Controlled Trial

(2012) P. De Simone et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)

(2012) René Adam et al.   JOURNAL OF HEPATOLOGY

Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: A meta-analysis

(2012) Wenhua Liang et al.   LIVER TRANSPLANTATION

Mammalian Target of Rapamycin (mTOR) Inhibitors

(2011) Sofia Sofroniadou et al.   DRUG SAFETY

mTOR inhibitor–associated proteinuria in kidney transplant recipients

(2011) Fritz Diekmann et al.   Transplantation Reviews

Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients

(2010) H. Tedesco Silva Jr. et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China

(2009) Jia Fan et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Liver Transplantation for Hepatocellular Carcinoma: Hangzhou Experiences

(2009) Shu-Sen Zheng et al.   TRANSPLANTATION

Calcineurin inhibitor minimization protocols in liver transplantation

(2008) Stefan A. Farkas et al.   TRANSPLANT INTERNATIONAL

The Difference and the Transition of Indication for Adult Living Donor Liver Transplantation Between the West and the East

(2008) W.T. Bo et al.   TRANSPLANTATION PROCEEDINGS